TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02932150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily
Study: NCT00688688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Extended release capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Mirabegron
Description: Matching mirabegron placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Tolterodine
Description: Matching tolterodine placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Tolterodine
Description: Matching tolterodine placebo capsules.
Study: NCT04404140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered at a dose of 400 mg, as per the dosing schedule described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 mg, as per the dosing schedule described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 75 mg/m\^2, as per the dosing schedule described above.
Study: NCT03802877

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resource bank
Description: See intervention arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource bank
Description: See intervention arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource bank
Description: See intervention arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource bank
Description: See intervention arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePlatform
Description: See intervention arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePlatform
Description: See intervention arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coach
Description: See intervention arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coach
Description: See intervention arm descriptions
Study: NCT03887962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Environment Biofeedback
Description: Treadmill walking. Modified available technology for gait capture. Tailored software for virtual environment rendering and immersive qualities

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill walking with no Virtual Environment Biofeedback
Description: Treadmill walking. Flat screen / no virtual environment to act as attentional control.
Study: NCT03992911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmtecan, 5-FU and l-LV
Description: Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide, Cisplatin
Description: Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide, Carboplatin
Description: Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
Study: NCT02803840

Intervention type: RADIATION
Group type: OTHER
Intervention: Low-dose radiotherapy
Description: 2 x 2 Gy on symptomatic sites only
Study: NCT03461887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention.
Study: NCT01314495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept will be administrated as a 30 minute intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive infusion
Description: Placebo will be administered as a 30 minute intravenous infusion.
Study: NCT01141179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 27847
Description: 2 mL (0.1 mg) dose of oral solution
Study: NCT05455944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Two capsules of pregabalin is administered orally to patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two identical placebo capsules is administered orally to patients
Study: NCT04061382

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: One study visit will be conducted by research study staff and blood sampling will be carried out.~Up to three follow-up visits will be conducted for a percentage of participants, where additional blood samples will be collected. The blood sample will initially focus on looking at population immunity to diphtheria, group C invasive meningococcal disease and SARS-CoV-2.

Intervention type: PROCEDURE
Intervention: Oral fluid swab
Description: Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.

Intervention type: PROCEDURE
Intervention: Oral fluid swab
Description: Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.

Intervention type: PROCEDURE
Intervention: Oral fluid swab
Description: Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.
Study: NCT01235429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners in Care
Description: Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
Study: NCT06229782

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Orbital Doppler ultrasonography
Description: During measurement, Doppler settings were adjusted to detect low flow and the smallest available Doppler gate was used for all ODUS examinations. The imaging probe position for ODUS was used transversely and axially, and mean values were recorded. ODUS 10-18 MHz linear probe was used.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transcranial Doppler ultrasonography
Description: During the measurement, Doppler settings were adjusted to detect low flow, and the minor available Doppler gate was used for all TDUS examinations. For TDUS, a temporal window was used approximately 1 cm above the midpoint of the line joining the lateral palpebral fissure and the external auditory meatus.~Transcranial Doppler ultrasonography ( TDUS) 3-5 MHz convex array probe was used.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Computed Tomography Angiography
Description: Cranial Computed Tomography Angiography
Study: NCT02225509

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FNA biopsy for thyroid nodule(s)
Description: The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.~The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit.
Study: NCT03512990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bupivacaine - Superior Trunk Block
Description: It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
Study: NCT04250714

Intervention type: DEVICE
Intervention: Boston Scientific Cardiac Cryoablation System
Description: cryoablation of atrial fibrillation consisting in electrical isolation of the pulmonary veins
Study: NCT02684487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
Study: NCT02218983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT02811484

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide-LAR plus Dapagliflozin placebo
Description: Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide-LAR plus Dapagliflozin
Description: Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Titration
Description: Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Titration
Description: Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Titration
Description: Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Therapy
Description: Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Therapy
Description: Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
Study: NCT02183025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefenamic acid 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching 7.5 mg meloxicam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching 7.5 mg meloxicam
Study: NCT00121173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Description: recombinant DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Description: recombinant DNA vaccine
Study: NCT02183025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching 15 mg meloxicam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching 15 mg meloxicam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching 500 mg mefenamic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching 500 mg mefenamic acid
Study: NCT00121173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Description: recombinant DNA vaccine
Study: NCT03110731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Physical training (2x / week) was performed for 12 weeks
Study: NCT00721266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
Study: NCT00781508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sildenafil
Description: Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Changes in left ventricular filling pressure 1 hour after oral administration of placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Changes in left ventricular filling pressure 1 hour after oral administration of placebo
Study: NCT03988413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg
Description: SYHA1402 25mg or Placebo 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg
Description: SYHA1402 50mg or Placebo 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg
Description: SYHA1402 100mg or Placebo 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg
Description: SYHA1402 200mg or Placebo 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg
Description: SYHA1402 400mg or Placebo 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg
Description: SYHA1402 800mg or Placebo 800mg
Study: NCT03325699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART4MD Health Application
Description: SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.~The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities.
Study: NCT03448055

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Immunocal
Description: cysteine-rich whey protein isolate
Study: NCT02487628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HQ® Matrix Soft Tissue Mesh

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ULTRAPRO® Partially Absorbable Lightweight Mesh
Study: NCT03882008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
Study: NCT04490824

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KELEA Excellerated Water
Description: Water with increased kinetic activity as assessed by published methods of the PI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KELEA Excellerated Water
Description: Water with increased kinetic activity as assessed by published methods of the PI

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Water Without an Elevated Level of KELEA
Description: Bottled water without an elevated level of KELEA, as shown by proprietary testing will be provided as a control.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water Without an Elevated Level of KELEA
Description: Bottled water without an elevated level of KELEA, as shown by proprietary testing will be provided as a control.
Study: NCT02545140

Intervention type: OTHER
Intervention: No intervention
Study: NCT03271996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistulectomy
Description: Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
Study: NCT04166058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)
Description: Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)
Description: Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)
Description: Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Description: Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Randomized doses (72 μg or 145 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Description: Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Randomized doses (72 μg or 145 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
Study: NCT03046173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concentrated growth factors
Description: These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hydroxyapatite and autogenous bone
Description: These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
Study: NCT03110744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: application on 21 consecutive days of a 28 days cycle
Study: NCT00117286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
Study: NCT03411915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb18087
Description: monoclonal bispecific antibody